november 1-2, 2019 - md anderson cancer center...jul 19, 2010 · the session entitled, heritable...

UPDATE ON THE MANAGEMENT OF

Genitourinary Malignancies

November 1-2, 2019The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB) Floor 8, Rooms 1-8 1155 Pressler Street Houston, Texas

Program Directors

Jose A. Karam, MD (Chair)Associate ProfessorUrology

Matthew T. Campbell, MD (Co-Chair)Assistant ProfessorGenitourinary Medical Oncology

Brian F. Chapin, MD (Co-Chair)Associate ProfessorUrology

14th

FocusThis conference will highlight innovative, multidisciplinary and novel treatment approaches for the treatment of complex genitourinary malignancies for the practicing urologist and medical oncologist that might not be currently either available or feasible in their home practice.

This activity will also inform practicing urologists and medical oncologists on ongoing research (clinical and translational) that will lead to further developments in our field that will lead to potentially fundamental changes in the treatment paradigm for patients with genitourinary malignancies.

The long-term goals of this activity are that attendees are better equipped to treat patients with genitourinary malignancies, that there is an increased awareness of new developments and research in the and an increased utilization of multidisciplinary approaches to the treatment of patients.

Educational ObjectivesAfter attending the conference, participants should be able to:

• Evaluate, counsel and treat patients with rare genitourinary malignancies (penile cancer, testicular cancer, and germ cell tumors) (Knowledge, Competence, Performance, Patient Outcomes);

• Utilize surgery and therapies for patients with kidney cancer (small renal masses, locally advanced tumors/adjuvant therapy, metastatic tumors/cytoreductive surgery, and systemic therapy) (Knowledge, Competence, Performance, Patient Outcomes);

• Assess patients with urothelial carcinoma (molecular characterization, non-muscle invasive tumors, muscle-invasive tumors, and systemic therapy) (Knowledge, Competence);

• Evaluate, counsel and treat patients with prostate cancer (screening, early disease/focal therapy, radiation therapy, high-risk disease, and recurrent/metastatic disease) (Knowledge, Competence, Performance, Patient Outcomes).


Genitourinary Malignancies14th

Educational MethodsLecture/Didactic – Case Study – Panel Discussion – Question and Answer Sessions – Poster Session – Skills- Based Training

Target AudienceThis conference should be of value to Urologists, Medical Oncologists, Physician Assistants, and Advanced Nurse Practitioners.

EvaluationA course evaluation will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit DesignationPHYSICIANS

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ETHICSThe session entitled, Heritable Genitourinary Cancers-When to Screen and What to Do Next, has been designated by The University of Texas MD Anderson Cancer Center for 1.00 AMA PRA Category 1 Credits™ in medical ethics and/or professional responsibility.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding AMA PRA Category 1 Credits™ or certificates documenting attendance will be emailed when an individual completes the online CME Verification process after the conference.


Genitourinary Malignancies

CALL FOR AbstractsAbstracts will be selected for poster presentation at the conference.

Please submit abstracts via e-mail to [email protected].

MD Anderson Organizing CommitteePROGRAM DIRECTORS




CONFERENCE COMMITTEE

Ana Aparicio, MDAssociate ProfessorGenitourinary Medical Oncology

John Davis, MDAssociate Professor Urology

Neema Navai, MDAssociate Professor Urology

Curtis A. Pettaway, MDProfessorUrology

Amishi Shah, MDAssistant ProfessorGenitourinary Medical Oncology

Arlene Siefker-Radtke, MDProfessorGenitourinary Medical Oncology

Nizar M. Tannir, MDProfessor and Ad-Interim ChairmanGenitourinary Medical Oncology

Christopher G. Wood, MDProfessor and Vice ChairmanUrology

Carol FourtuniaAdministrative CoordinatorUrology

Allison Baring, CMPCME Conference PlannerCME Conference Management

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

AGENDAFriday November 1, 2019

7:00 am Registration/Continental Breakfast

7:50 Welcome/Opening Remarks Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD

SESSION I: Renal Cell CarcinomaModerators:Christopher G. Wood, MD and Nizar M. Tannir, MD

Management of the Small Renal Mass: What is the Best Approach?

8:00 Active Surveillance Surena Matin, MD

8:10 Ablation Kamran Ahrar, MD

8:20 Partial Nephrectomy Jeffrey J. Tomaszewski, MD

8:30 Question and Answer Session

Locally Advanced Renal Cell Carcinoma

8:45 Is There a Role for Neoadjuvant Therapy in the Management of Locally Advanced Renal Cell Carcinoma? Christopher G. Wood, MD

9:00 Update on Adjuvant Therapy in Kidney Cancer: Recent Results and Ongoing Trials Jose A. Karam, MD


9:30 Break

Metastatic Renal Cell Carcinoma: What is the Best First-Line Systemic Therapy for Intermediate/Poor Risk Clear-Cell RCC?

9:45 A PD-1 or PD-L1 Antibody + VEGF Targeted Therapy Matthew T. Campbell, MD

9:55 Nivolumab + Ipilimumab Jianjun Gao, MD, PhD

What is the Best First-Line Systemic Therapy for Favorable-Risk Clear-Cell RCC?

10:05 PD-1 or PD-L1 Antibody + VEGF Targeted Therapy Amishi Shah, MD

10:15 A Sequential Therapy of VEGFR-TKI Followed by Immune Checkpoint Inhibitor(s) Pavlos Msaouel, MD, PhD

10:25 Debate on the Role of Cytoreductive Nephrectomy (CN) in the Era of Immune Checkpoint Inhibitors and Targeted Therapies

Pro: There is Still a Role for CN in the Era of Immune Checkpoint Inhibitors (ICI) and Targeted Therapies Robert Uzzo, MD

Con: CN Should No Longer be Considered Standard of Care in the Era of ICI and Targeted Therapies Eric Jonasch, MD

10:50 Update on Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma: Have We Made Any Progress? Nizar M. Tannir, MD


11:20 Case Presentations Moderator: Christopher G. Wood, MD Panelists: Kamran Ahrar, MD; Jianjun Gao, MD, PhD; Eric Jonasch, MD;

Jose A. Karam, MD; Surena Matin, MD; Amishi Shah, MD; Nizar M. Tannir, MD; Jeffrey J. Tomaszewski, MD and Robert Uzzo, MD

12:05 pm Lunch (Provided)

SESSION II: Rare GU TumorsModerators: Curtis A. Pettaway, MD and Amishi Shah, MD

Advanced Urethral Cancer- What is the Best Local Control Strategy? Case of Advanced Urethral Tumor

1:00 Chemotherapy Role and Considerations Amishi Shah, MD

1:10 Consolidation Residual Disease

Radiation is Best Patricia J. Eifel, MD

Surgery is Best Curtis A. Pettaway, MD

Case of Advanced Urethral Tumor-Continued Advanced Penile Cancer

1:30 Role of Adjuvant Radiotherapy in Penile Cancer-Who Benefits? Karen Hoffman, MD

1:45 Update on the InPACT Trial Curtis A. Pettaway, MD

2:00 When Chemotherapy Fails- What’s Next? Jad Chahoud, MD


2:30 Break

Advanced Germ Cell Tumor

3:00 Postchemotherapy RPLND for Germ Cell Tumors: Indications, Outcomes and Complications Jose A. Karam, MD

3:15 Stem cell Transplant in Advanced GCT Yago Nieto, MD, PhD

3:30 Case Presentations Matthew T. Campbell, MD

3:50 Break

4:00 Andrew C. von Eschenbach Lecture Series Robert Uzzo, MD

Distinguished Alumni Lectures

4:40 Department of Urology David A. Swanson Distinguished Alumni Lecture Series M. Derya Balbay, MD (Class of 1999)

Department of GU Medical Oncology Vasiliki Tzelepi, MD (Class of 2010)

5:30 pm Adjourn/Reception

Saturday November 2, 2019

7:00 am Registration/Continental Breakfast

7:50 Welcome/Opening Remarks Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD

SESSION III: Bladder/Upper Tract CancersModerators: Neema Navai, MD and Arlene O. Siefker-Radtke, MD

Upper Tract Urothelial Carcinoma

8:00 Clinical and Translational Updates in Upper Tract Urothelial Carcinoma Surena Matin, MD

Non-Muscle-Invasive Bladder Cancer (NMIBC) and Muscle-Invasive-Bladder Cancer (MIBC)

8:15 Clinically Node Positive Bladder Cancer- When Should Surgery Be Applied? Neema Navai, MD

8:30 Can Some Patients with MIBC be Cured with Systemic Therapy Alone? Matthew T. Campbell, MD

8:45 Trimodal Therapy or Radical Cystectomy: Which Provides Best Local Control?

Trimodal Therapy Chad Tang, MD

Radical Cystectomy H. Barton Grossman, MD

9:05 Challenges and Opportunities in the BCG Shortage Era Ashish Kamat, MD

9:20 Gene Therapy for Bladder Cancer – From Bench to Bedside Colin P. Dinney, MD

9:35 Case Presentations: NMIBC Neema Navai, MD

9:45 Case Presentations: MIBC Ashish Kamat, MD


10:05 Break

* Indicates ethics credit

Metastatic Urothelial Carcinoma

10:25 New Agents/New Approvals: Where Do We Go From Here? Arlene O. Siefker-Radtke, MD

10:40 Combination IO trials in Metastatic Urothelial Carcinoma -Translational and Clinical Data Jianjun Gao, MD, PhD

10:55 When C-Met Inhibitors and UC Meet: Early Evidence for Clinical Activity Pavlos Msaouel, MD, PhD

11:05 Challenging Cases in Metastatic UC and IO Toxicity Matthew T. Campbell, MD


11:35 Break

SESSION IV: Prostate CancerProstate Biopsy Seminar-Multidisciplinary Approach

11:50 MRI Based Selection for Fusion Prostate Biopsy—Interpretation Haesun Choi, MD

12:00 pm Prostate Fusion Biopsy- How I Do It John F. Ward, MD

12:15 Transperineal Free Hand Biopsy- How I Do It Lisly J. Chery, MD

12:30 Case Presentations


1:00 Ethics Lecture (Lunch provided) Heritable Genitourinary Cancers-When to Screen and What to Do Next?* Ashley H. Woodson, MS

Radiation Therapy in Prostate Cancer

2:00 Proton Therapy for Prostate Cancer – Long Term Results Chad Tang, MD

2:15 The Role of Site-Directed Radiation Therapy in Metastatic Patients Quynh-Nhu Nguyen, MD


High-Risk Prostate Cancer

2:40 Role of PET Imaging in Prostate Cancer Aradhana M. Venkatesan, MD

2:55 The Punch Trial is out...What Next? Brian F. Chapin, MD

3:10 Clinical Trials for High-Risk Clinically Localized Disease Eleni Efstathiou, MD, PhD

3:25 Salvage Robotic Assisted Radical Prostatectomy – State of the Art Louis L. Pisters, MD

3:40 Case Presentations

Recurrent/Metastatic Prostate Cancer

4:00 Management of Biochemical Relapse Post RP/RT Justin R. Gregg, MD

4:15 Systemic Therapy for Hormone Naïve Metastatic Prostate Cancer Ana Aparicio, MD


4:45pm Adjourn

MD Anderson Faculty Kamran Ahrar, MDProfessorInterventional Radiology

Ana Aparicio, MDAssociate ProfessorGenitourinary Medical Oncology



Lisly J. Chery, MDAssistant ProfessorUrology Surgery-Sugar Land

Haesun Choi, MDProfessorAbdominal Imaging Department

Colin P. Dinney, MDChair Urology

Eleni Efstathiou, MD, PhDAssociate ProfessorGenitourinary Medical Oncology

Patricia J. Eifel, MDProfessorRadiation Oncology

Jianjun Gao, MD, PhDAssistant ProfessorGenitourinary Medical Oncology

Justin R. Gregg, MDAssistant ProfessorUrology

H. Barton Grossman, MDClinical ProfessorUrology

Karen Hoffman, MDAssociate ProfessorRadiation Oncology

Eric Jonasch, MDProfessorGenitourinary Medical Oncology

Ashish Kamat, MDProfessorUrology


Surena Matin, MDProfessor Urology

Pavlos Msaouel, MD, PhDAssistant ProfessorGenitourinary Medical Oncology

Neema Navai, MDAssociate ProfessorUrology

Quynh-Nhu Nguyen, MDAssociate ProfessorRadiation Oncology

Yago Nieto, MD, PhDProfessorStem Cell Transplantation

Curtis A. Pettaway, MDProfessorUrology

Louis L. Pisters, MDProfessorUrology

Amishi Shah, MDAssistant ProfessorGenitourinary Medical Oncology

Arlene O. Siefker-Radtke, MDProfessorGenitourinary Medical Oncology

Chad Tang, MDAssistant ProfessorRadiation Oncology

Nizar M. Tannir, MDProfessor and Ad-Interim ChairmanGenitourinary Medical Oncology

Aradhana M. Venkatesan, MDAssociate ProfessorAbdominal Imaging Department

John F. Ward, MDProfessor Urology

Ashley H. Woodson, MSSenior Genetic CounselorClinical Cancer Genetics

Christopher G. Wood, MDProfessor and Vice-ChairmanUrology

Guest FacultyJad Chahoud, MDMoffitt Cancer CenterTampa, Florida

Jeffrey J. Tomaszewski, MDDirectorGenitourinary Oncology ProgramMD Anderson Cancer Center at CooperCamden, New Jersey

Andrew C. von Eschenbach Lecture SeriesRobert Uzzo, MD, FACSChairSurgical OncologyG. Willing "Wing" Pepper ChairCancer ResearchKidney, Bladder, and Prostate Cancer TRDG MemberSenior Vice-PresidentPhysician ServicesPresidentFox Chase Cancer Center Medical Group, Inc.Professor of SurgeryTemple University Health SystemPhiladelphia, Pennsylvania

Distinguished Alumni Lectures

Department of Urology

David A. Swanson Distinguished Alumni Lecture SeriesM. Derya Balbay, MDProfessorUrologyKOC University HospitalIstanbul, Turkey

Department of GU Medical OncologyVasiliki Tzelepi, MDAssistant ProfessorPathologyUniversity of PatrasPatras, Greece

Registration InformationOn-site registration opens at 7:00 am on Friday, November 1. The conference will begin at 7:50 am and adjourn at 4:45 pm on Saturday, November 2. Advanced registration is encouraged as space and materials are limited.

The deadline for advanced registration is Friday, October 11, 2019.

There are three ways to register:

1. On-line at www.mdanderson.org/conferences2. Fax to: 713-794-17243. Mail to: CME/Conference Management

Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407

We accept the following forms of payment:• Check (payable through U.S. banks only)• Money Order• Credit Cards (MasterCard, VISA, and American Express)• Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and a reception. Please refer to the registration form for specific information regarding fees.

REFUND/CANCELLATION POLICY

The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before October 11, 2019. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

SPECIAL ASSISTANCE

Contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

ACCOMMODATIONS

• A block of rooms has been reserved for conference attendees at the InterContinental Houston – Medical Center located at 6750 Main Street, Houston, Texas.

• Book your room online at: https://bit.ly/2Yv1aWt

• The hotel phone number is (713) 422-2779.

• Early hotel reservation is suggested and the room block cutoff date is Thursday, October 10, 2019.

• When you make reservations, be sure to mention the group name: 14th Update on the Management of Genitourinary Malignancies Conference to be assured of receiving the special meeting rate of $179/nigh for a single/double guest room. Please add 17% Texas state and local taxes.

GROUND TRANSPORTATION (prices are subject to change and variable depending on location of conference)

• Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). The following forms of ground transportation are available to and from both airports:

• Uber or Lyft • Yellow Cab- 713.236.1111 • Super Shuttle: For more information, call toll free at 800.258.3826 or visit

www.supershuttle.com

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

CO

NFE

REN

CE

REG

ISTR

ATI

ON

- 17

6700

/30/

1217

19/4

114

th U

pdat

e on

the

Man

agem

ent o

f Gen

itour

inar

y M

alig

nanc

ies

Nove

mbe

r 1-2

, 201

9La

st N

ame

Firs

tM

IHi

ghes

t Deg

ree

Depa

rtmen

t (in

clud

e un

it no

.)

Spec

ialty

Inst

itutio

n

MD

Ande

rson

Em

ploy

ee ID

No.

(req

uire

d fo

r all

MDA

CC e

mpl

oyee

s):

Phys

icia

n Y

es

No

Stre

et

City

Stat

e/Fo

reig

n Co

untry

/Zip

or M

ail C

ode

Dayt

ime

Phon

e (w

ith a

rea

code

) Ce

ll Ph

one

(with

are

a co

de)

Fax

(with

are

a co

de)

E-m

ail A

ddre

ss (

plea

se p

rint)

Emer

genc

y Co

ntac

tPh

one

(with

are

a co

de)

Cred

it Ca

rd H

olde

r Nam

e (F

irst/

Last

) Ch

arge

the

follo

win

g: V

ISA

M

C

AM

EX

Cred

it Ca

rd N

umbe

rEx

pira

tion

Date

Secu

rity

Code

/CVV

/CSV

Cred

it Ca

rd H

olde

r Bill

ing

Addr

ess

& Z

IP C

ode

MD

And

erso

n In

terd

epar

tmen

tal T

rans

fer (

IDT)

No.

: *F

und

Grou

p 90

will

not

be

acce

pted

Bus

ines

s U

nit

D

epar

tmen

tFu

nd G

roup

*Fu

ndFu

nd T

ype

Aut

hori

zed

Sign

atur

e RE

QU

IRED

for C

RED

IT C

ARD

or I

DT

IDT

Appr

over

Nam

e (F

irst/L

ast)

plea

se p

rint

THIS

IS N

OT A

SEL

F-M

AILE

R - A

ddre

ss to

: 14

th U

pdat

e on

the

Man

agem

ent o

f Ge

nito

urin

ary

Mal

igna

ncie

sCM

E/Co

nfer

ence

Man

agem

ent –

Uni

t 178

1Th

e Un

ivers

ity o

f Tex

as M

D An

ders

on C

ance

r Cen

ter

PO B

ox 3

0140

7, H

oust

on, T

X 77

230-

1407

or fa

x to

713-

794-

1724

M

ake

chec

k or m

oney

ord

er p

ayab

le to

: Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r

Regi

stra

tion

Fees

Phys

icia

ns (M

D’s

/DO

’s) a

nd S

cien

tists

...

....

..$2

75

Stud

ents

/ Tr

aine

es /

PAs

/ A

dvan

ced

Nur

se P

ract

ition

ers .

....

....

....

....

.$60

One

Day

Fee

...

....

....

....

....

....

....

....

...$30

o

Nov

embe

r 1o

Nov

embe

r 2

Will

you

be

atte

ndin

g th

e Fr

iday

eve

ning

rece

ptio

n?

oYe

so

No

CME/

Conf

eren

ce M

anag

emen

t- Un

it 17

81Th

e Un

iver

sity

of T

exas

MD

Ande

rson

Can

cer C

ente

r17

6700

/30/

1217

19/4

1PO

Box

301

407

Hous

ton,

TX

7723

0-14

07

Non

-Pro

fit O

rg.

U.S.

Pos

tage

P A

I DHo

usto

n, T

XPe

rmit

No.

705

2

november 1-2, 2019 - md anderson cancer center...jul 19, 2010 · the session entitled, heritable...

Documents